Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-3 long-term open-label extension of KarXT + KarX-EC for agitation associated with Alzheimer's disease
CTR20262871Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline, KarX-EC, trospium in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Started Jul 2026; status: active.
02
Drugs
xanomelineKarX-ECtrospium
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20262871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262871.